Condition: Tobacco Use Disorder · Nicotine Dependence · Cigarette Smoking · Sponsor: University of Oklahoma
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
This description comes directly from the study's public registry record.
Jason A Oliver, PhD · 405-271-8001 · Jason-Oliver@ouhsc.edu
Isabel Brush, B.A. · Isabel-Brush@ouhsc.edu
Always discuss trial participation with your own doctor first.
| Hardesty Center for Clinical Research and Neuroscience | Tulsa, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05587361